Florida court to hear connection between abilify and gambling addiction
Florida Court to Hear Abilify Gambling Addiction Cases
August 2, 2017
The U.S. District Court of the Northern District of Florida will begin hearing cases concerning the links between addictive gambling behavior and the anti-psychotic medication Abilify.
At issue in the Multi-District Litigation (MDL) case is whether Bristol-Myers Squibb and Otsuka Pharmaceutical, the manufacturers of Abilify, manufactured an allegedly defective and/or dangerous drug, and whether the companies knowingly concealed information about Abilify’s risks from doctors and patients.
The Florida hearings are part of the discovery phase of the MDL case, and will take place in Tallahassee and Pensacola.
Abilify has been the subject of numerous complaints, nearly all of which focus on the drug’s unusual side effect: the alleged creation of addictive behavior: gambling, binge eating, compulsive shopping, and addictive sexual behaviors.
Abilify’s label contained no mention of these potential hazards until 2016, the same year in which the drug’s makers paid nearly $20 million to settle claims of unfair or deceptive trade practices concerning the marketing of Abilify.
Abilify earned the companies about $5.5 billion in sales in 2014.
If you’ve taken Abilify and have developed addictive behaviors, you may be entitled to be part of a lawsuit. The expert attorneys at TheLawFirm.com can help you with your case – call for a free consultation.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!